ÔÚÒ»ÏîеÄÑо¿ÖÐ £¬£¬£¬À´×Ô°¢¶û²®ÌØ-°®Òò˹̹ҽѧԺµÄÑо¿Ö°Ô±È¡µÃÁËÖØ´óÏ£Íû £¬£¬£¬ËûÃÇ·¢Ã÷ÁËÒ»ÖÖ¸ÄÁ¼µÄCAR-Tϸ°ûÁÆ·¨ £¬£¬£¬¸ÃÁÆ·¨Õë¶ÔʵÌåÁöÕ¹ÏÖ³öÁËب¹ÅδÓеÄÁÆЧ £¬£¬£¬ÕâһЧ¹û»ò½«ÖØËÜ°©Ö¢ÖÎÁÆÃûÌᣡ£¡£¡£¡£¡£Ïà¹ØÑо¿Ð§¹û½üÆÚ½ÒÏþÔÚScience AdvancesÆÚ¿¯ÉÏ £¬£¬£¬ÂÛÎÄÎÊÌâΪ¡°TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors¡±¡£¡£¡£¡£¡£¡£
Ñо¿Í¨Ñ¶×÷ÕßXingxing Zang²©Ê¿ÌåÏÖ£º¡°CAR-Tϸ°ûÁÆ·¨ÔÚѪ°©ÖÎÁÆÁìÓòÒÑÈ¡µÃ¸ïÃüÐԳɼ¨ £¬£¬£¬µ«ÔÚʵÌåÁöÑÛÇ°È´Ò»ÔÙÊÜ´ì¡£¡£¡£¡£¡£¡£ÎÒÃǾªÏ²µØ·¢Ã÷ £¬£¬£¬Í¨¹ýÓÅ»¯±ê×¼CAR-Tϸ°ûÁÆ·¨ £¬£¬£¬Æä¶ÔʵÌåÁö £¬£¬£¬ÓÈÆäÊÇÒÈÏÙ°©ºÍ½ºÖÊĸϸ°ûÁöÕâÀàÄÑÖÎÐÔ°©Ö¢µÄÖÎÁÆЧ¹û»ñµÃÁËÏÔÖøÌáÉý¡£¡£¡£¡£¡£¡£¡±
¿ª·¢¸öÐÔ»¯°©Ö¢É±ÊÖ
Zang²©Ê¿ºÍËûµÄͬÊÂÃÇ¿ª·¢³öÎåÖÖCAR-Tϸ°ûÁÆ·¨ £¬£¬£¬²¢ÔÚÒÆÖ²ÁËÈËÀàʵÌåÁöµÄСÊóÄ£×ÓÉϾÙÐÐÁËʵÑé¡£¡£¡£¡£¡£¡£ÆäÖÐ £¬£¬£¬Ò»ÖÖÁÆ·¨ÒòÈÚºÏÁËÁ½ÏîÐÂÓ±ÔªËضøÍÑÓ±¶ø³ö £¬£¬£¬Ëü²»µ«Çå¾²ÓÐÓõØËõ¼õÁ˽ºÖÊĸϸ°ûÁöºÍÒÈÏÙÖ×Áö £¬£¬£¬Í¬Ê±Ò²¶Ô·Î°©Ö×Áö±¬·¢ÁËÏÔÖøµÄÒÖÖÆЧ¹û¡£¡£¡£¡£¡£¡£
CAR-Tϸ°ûÁÆ·¨ £¬£¬£¬È«³ÆǶºÏ¿¹ÔÊÜÌåTϸ°ûÁÆ·¨ £¬£¬£¬±»ÓþΪ»ùÒò¹¤³ÌµÄ½Ü×÷ £¬£¬£¬Äܹ»½«ÃâÒßϵͳÖеÄTϸ°ûת»¯Îª¾«×¼¹¥»÷°©Ï¸°ûµÄ¡°»îÌåµ¼µ¯¡±¡£¡£¡£¡£¡£¡£¸ÃÁÆ·¨Éæ¼°´Ó»¼ÕßÌåÄÚÌáÈ¡Tϸ°û £¬£¬£¬²¢Í¨¹ý»ùÒò¹¤³ÌÊÖÒÕÖ²Èë±àÂëCARµÄ»ùÒò¡£¡£¡£¡£¡£¡£¾ÓÉˢеÄCAR-Tϸ°û¿ÉÔÚÌåÍâ´ó×ÚÀ©Ôö £¬£¬£¬Ëæºó»ØÊäÖÁ»¼ÕßÌåÄÚ £¬£¬£¬ÆäÍâò±í´ïµÄºÏ³ÉCARÊÜÌåÄܹ»Ê¶±ð²¢Ëø¶¨°©Ï¸°ûÉϵÄÌض¨¿¹Ô £¬£¬£¬´¥·¢Tϸ°ûµÄ¹¥»÷»úÖÆ¡£¡£¡£¡£¡£¡£
ÎåÖÖCAR-Tϸ°û¶Ô¿¹ÈýÖÖ°©Ö¢
Zang²©Ê¿ÍŶӵÄÎåÖÖCAR-Tϸ°ûÁÆ·¨¾ù½ÓÄÉÁËͳһÖÖÐÂÐ͵İÐÏòÂѰסª¡ªÒ»ÖÖÄÜÓëB7-H3Á¬ÏµµÄµ¥¿Ë¡¿¹Ìå £¬£¬£¬B7-H3ÊÇÒ»ÖÖÆձ鱣´æÓÚ´ó¶¼ÊµÌåÁö¼°ÆäѪ¹ÜÍâòµÄ¿¹Ô¡£¡£¡£¡£¡£¡£ÔÚ´ËÇ°µÄÑо¿ÖÐ £¬£¬£¬Zang²©Ê¿ÒÑÕ¹ÏÖB7-H3ÔõÑù×ÌÈÅTϸ°û¹¦Ð§ £¬£¬£¬ÐÖúÖ×ÁöÌÓ×ßÃâÒßϵͳµÄ×·²¶¡£¡£¡£¡£¡£¡£ÎªÁËսʤÕâÒ»ÕÏ° £¬£¬£¬Zang²©Ê¿Ö¸³ö£º¡°ÎÒÃÇÏ£ÍûÉè¼ÆµÄCAR²»µ«ÄÜÖ¸µ¼Tϸ°û¶¨Î»ÊµÌåÁö £¬£¬£¬»¹ÄÜͨ¹ýÌØÒìÐÔÁ¬ÏµB7-H3 £¬£¬£¬×èÖ¹ÆäÏ÷ÈõTϸ°û¹¥»÷ºÍɨ³ý°©Ï¸°û¼°ÆäѪ¹ÜµÄÄÜÁ¦¡£¡£¡£¡£¡£¡£¡±
È»¶ø £¬£¬£¬½ö¿¿Á¬ÏµÖ×Áöϸ°ûÉÐȱ·¦ÒÔÈ·±£°©Ï¸°ûµÄéæÃü¡£¡£¡£¡£¡£¡£ÎªÁ˼¤»îTϸ°û £¬£¬£¬CAR»¹Ðè°üÀ¨Ò»ÖÖ¹²´Ì¼¤ÂѰס£¡£¡£¡£¡£¡£ÔÚZang²©Ê¿ÊµÑéÊÒÑз¢µÄÎåÖÖCAR-Tϸ°ûÁÆ·¨ÖÐ £¬£¬£¬ËÄÖÖ½ÓÄÉÁË´«×ܹ²´Ì¼¤ÂÑ°× £¬£¬£¬¶øµÚÎåÖÖÔòÒýÈëÁËÒ»ÖÖب¹ÅδÓеÄÂѰסª¡ªTMIGD2¡£¡£¡£¡£¡£¡£
2015Äê £¬£¬£¬Zang²©Ê¿·¢Ã÷Tϸ°ûÓµÓÐÒ»ÖÖ³ÆÖ®TMIGD2µÄÊÜÌå £¬£¬£¬ÕâÖÖÊÜÌåÔÚÊܵ½´Ì¼¤Ê±Äܼ¤»îTϸ°û£¨Clinical Cancer Research, 2025, doi:10.1158/1078-0432.CCR-14-1495£©¡£¡£¡£¡£¡£¡£ËûØʺóÒâʶµ½ £¬£¬£¬½«TMIGD2ÕûÈëµ½CAR-Tϸ°û¿ÉÄÜʹËüÃÇսʤʵÌåÁö´øÀ´µÄÌôÕ½¡£¡£¡£¡£¡£¡£
ͼƬÀ´×ÔScience Advances, 2024, doi:10.1126/sciadv.adk1857
¡°ÊµÌåÁöÄÚ²¿µÍÑõÌõ¼þÓëÃâÒß¼ì²éµãµÄ±£´æ £¬£¬£¬ÐγÉÁËÒ»¸ö¶ÔTϸ°û¼«Æäµ¹Ô˵Ä΢ÇéÐÎ £¬£¬£¬ÏÞÖÆÁËËüÃǵÄÉø͸ÄÜÁ¦ºÍÃâÒß¹¥»÷Á¦¡£¡£¡£¡£¡£¡£TMIGD2×÷Ϊ¹²´Ì¼¤ÂÑ°× £¬£¬£¬ËƺõÄܹ»ÎªCAR-Tϸ°û×¢Èë×ã¹»µÄ¶¯Á¦ £¬£¬£¬Ê¹Æ䴩͸ʵÌåÁöµÄ÷缯½áµÞ×éÖ¯ £¬£¬£¬µÖ´ï°©Ï¸°û²¢ºã¾ÃפÁô¡£¡£¡£¡£¡£¡£¡±Zang²©Ê¿Ú¹Ê͵À¡£¡£¡£¡£¡£¡£
TOP CAR
ʵÑéЧ¹ûÏÔʾ £¬£¬£¬Ð¯´øÒÈÏÙ°©¡¢·Î°©ºÍ½ºÖÊĸϸ°ûÁöµÄСÊóÔÚ½ÓÊÜÁËÐÂÐÍCAR-Tϸ°ûÁÆ·¨ºó £¬£¬£¬Õ¹ÏÖ³öÁîÈ˹ÄÎèµÄÁÆЧ¡£¡£¡£¡£¡£¡£ÆäÖÐ £¬£¬£¬×îÒýÈËעĿµÄÁÆ·¨Á¬ÏµÁËÐÂÐÍ¿¹ÌåÓëTMIGD2ÂÑ°× £¬£¬£¬±»ÃüÃûΪTMIGD2ÓÅ»¯Ð§Á¦/³¤ÆÚÐÔ£¨Optimized Potent/Persistent, TOP£©CAR¡£¡£¡£¡£¡£¡£
ʹÓÃTOP CARµÄCAR-Tϸ°ûÁÆ·¨ÔÚÒÈÏÙ¡¢·ÎºÍ½ºÖÊĸϸ°ûÁöСÊóÄ£×ÓÖÐÌåÏÖ׿Խ £¬£¬£¬ÏÔÖøÌá¸ßÁËСÊóµÄ´æ»îÂÊ¡£¡£¡£¡£¡£¡£ÀýÈç £¬£¬£¬ÔÚ½ºÖÊĸϸ°ûÁöСÊóÖÐ £¬£¬£¬TOP CAR Tϸ°ûÁÆ·¨Ê¹7Ö»ÖеÄ6Ö»´æ»îÏÂÀ´ £¬£¬£¬¶øÆäËûCAR-TÁÆ·¨½öÄÜÕü¾È3Ö»ÖеÄ1Ö»¡£¡£¡£¡£¡£¡£±ðµÄ £¬£¬£¬TOP CAR Tϸ°ûÁÆ·¨ÔÚÓÐÓÃÐÔºÍÇå¾²ÐÔÖ¸±êÉϾùÕ¹ÏÖ³öÓÅÊÆ¡£¡£¡£¡£¡£¡£
Õ¹ÍûδÀ´ £¬£¬£¬Zang²©Ê¿ÍýÏë½øÒ»²½ÍêÉÆTOP CARÊÖÒÕ £¬£¬£¬¹¹½¨Ò»¸ö¡°Ïֳɡ±Æ½Ì¨ £¬£¬£¬¸Ãƽ̨²»µ«ÄÜ°ÐÏòB7-H3 £¬£¬£¬»¹¿Éͬʱʶ±ð¶àÖÖÖ×Áö¿¹Ô £¬£¬£¬ÊÊÓÃÓÚÖÖÖÖʵÌåÁöµÄÖÎÁÆ¡£¡£¡£¡£¡£¡£
°¢¶û²®ÌØ-°®Òò˹̹ҽѧԺÒѶÔZang²©Ê¿µÄ¿ÆÑÐЧ¹û½ÓÄÉÁË֪ʶ²úȨ±£»£»£»¤²½·¥ £¬£¬£¬²¢ÕýÆð¾¢×·ÇóÉÌÒµÏàÖúͬ°é £¬£¬£¬Ö¼ÔÚ½«ÕâÖÖË¢ÐÂÐÔµÄTOP CAR Tϸ°ûÁÆ·¨¾¡¿ìÍƽøÖÁÁÙ´²ÊÔÑé½×¶Î £¬£¬£¬ÎªÄÔ°©¡¢¸Î°©¡¢ÒÈÏÙ°©¡¢Âѳ²°©¡¢Ç°ÏßÏÙ°©¡¢·Î°©¡¢°òë×°©ºÍ½á³¦°©µÈ¶àÖÖ°©Ö¢»¼Õß´øÀ´¸£Òô¡£¡£¡£¡£¡£¡£
